SELSUN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Selsun, and when can generic versions of Selsun launch?
Selsun is a drug marketed by Chattem and is included in one NDA.
The generic ingredient in SELSUN is selenium sulfide. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the selenium sulfide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Selsun
A generic version of SELSUN was approved as selenium sulfide by PADAGIS US on January 10th, 1991.
Summary for SELSUN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 24 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SELSUN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SELSUN
US Patents and Regulatory Information for SELSUN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chattem | SELSUN | selenium sulfide | LOTION/SHAMPOO;TOPICAL | 007936-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |